Neuronasal, LLC

Neuronasal is a clinical-stage pharmaceutical company developing a suite of therapeutics targeting large, unmet needs across the Central Nervous System (CNS) space. It provides an improved, alternative route of administration bypassing the blood-brain barrier (BBB) with pilot human data demonstrating proof-of-concept for direct N2B delivery for CNS indications. NAC is an FDA-approved drug with 30+ year safety record (via oral and IV delivery). Established preclinical and clinical molecular proof-of-concept in target patient populations. Company Pilot human data confirmed safe and effective brain delivery with novel, brain imaging technology. Open IND with a high likelihood of Phase I success. Protected by issued patents. Significant IP milestone achieved.  N2B NAC focused on Parkinson’s Disease (PD) with a potential dual path strategy encompassing both disease-modifying and symptom-relief indications. Opportunity to advance mTBI/Concussion program in parallel with several, additional CNS indications identified. Phase I N2B dose/formulation/device optimization study ready-to-go with FDA letter to proceed. Pledged support from leading PD foundations to fund Phase 2a and follow on.

Ophidion, Inc.

Ophidion Inc. is developing therapeutic interventions to treat Huntington’s disease (HD). Having demonstrated we can deliver siRNA into the brain following intravenous administration for our cognition indications, we are leveraging the power of our platform technology to deliver our proprietary siRNA to knockdown the expression of Huntingtin protein in the brain. Silencing the Huntington’s gene (HTT, both wildtype and mutant) has been shown to result in disease modification in animals. Ophidion raised $2 Million seed from a PA angel group in 2021. Recently raised an additional $1.5 million to continue their POC preclinical activities.

Young Therapeutics, LLC

Young Therapeutics, LLC is a biotech company focused on the prevention of Ischemia Reperfusion (I/R) injury. Young Therapeutics (YTx) is pursuing three related but distinct indications. These are: (i) preventing Ischemia/reperfusion injury (I/R I) in the setting of myocardial infarction, (ii) preventing I/R I following kidney transplant, Our Orphan designation has been granted for Kidney transplant. and (iii) preventing ischemic damage associated with various elective cardiac procedures. The founder of YTx is Lindon Young, Ph.D., a professor at the Philadelphia College of Osteopathic Medicine (PCOM). YTx has used approximately $900K of NIH funding to complete critical animal studies. 

Prima Innovation, LLC

Prima Innovation, LLC has discovered a novel and promising medication for treating muscle spasms. Currently, available therapeutics for muscle spasms are outdated and ineffective and produce serious treatment-limiting systemic side effects. Thus, the unmet need is tremendous. The need spans a broad range of patient conditions including multiple sclerosis, radiculopathies, and brain and spinal cord injuries, as well as common muscle strain and spasms from over-exertion and injury. PI-111, Restored Normal Function in a Torticollis Patient, an orphan indication characterized by muscle contracture on one side of the child's neck. 

Synergy Therapeutics, Inc.

The goal is to transform the lives of cancer patients by restoring the functions of p53, the guardian of the genome, to lengthen progression-free survival. Synergy Therapeutics has discovered and is developing a first-in-class oncology therapeutic that meets this target. Synergy’s disruptive fusion protein upregulates p53 by inhibiting both MDM2 and MDM4. It also promotes apoptotic cancer cell death pathways by inhibiting Bcl-xL and MCL-1. Synergy’s peptide is linked to human serum albumin (HSA) which enables heavy tumor loading by satisfying tumors’ hunger for amino acids and fatty acids. SYN-126 exhibits potent synergy with chemotherapeutics and kinase inhibitors, is tumoricidal and has potential to enhance immuno-oncology treatments. Synergy’s lead compound is SYN-126 which we are confident will slow treatment resistance to kinase inhibitors. Synergy was spun out from the Philadelphia College of Pharmacy and is based at the Pennsylvania Biotechnology Center in Doylestown. Synergy has a strong management team with extensive oncology experience. No p53-activating drugs have been approved based on either escape resistance driven by MDM4 (MDM2 homolog), unacceptable toxicity profile or lack of intracellular penetration. Synergy’s HSA technology provides a platform for targeting almost any drug to tumors and extending half-life. Synergy is raising a seed financing to advance SYN-126 into additional preclinical studies, followed by a rangefinder toxicology study as a go/no go milestone to begin IND-enabling studies.

CaperRx, Inc.

CaperRx, Inc. is a seed stage biopharmaceutical company spun out of St. Josephs University, focusing on a selective proprietary peptide inhibitor of an oncoprotein(CAPER) that cancer uses for survival. When CAPER is suppressed, tumor cells die, leaving normal cells untouched. This fundamental killing of tumor cells could have broad application. We expect little to no off-target effects. We are developing an oral formulation that crosses the blood brain barrier for our first indication targeting triple negative breast cancer (TNBC)the most aggressive of breast cancers that spreads to the brain resulting in shortened overall survival due to metastases. Treating early (neoadjuvant/adjuvant settings) could allow for better control of this aggressive cancer in conjunction with physicians choice of care with the goal of a pathologic complete response, a surrogate for overall survival in both US and EU regulatory agencies. TNBC attacks women less than 40 years old and a disproportionate number women of color. Meeting this high unmet need could allow for breakthrough designation and accelerated approval. 

They are seeking $1M to complete POC Preclinical Studies.

Stimbiotics, Inc.

StimBiotics Inc. is an early-stage Biotech company created by BusStim, LLC, a virtual biotech accelerator, and spun-out of New Mexico Tech. StimBiotics has pioneered a new class of patented small molecules that can work alone and synergistically with existing antibiotics to treat Multidrug-Resistant (MDR) microbes, demonstrating rapid killing of

both Gram-positive and Gram-negative pathogens. Additionally, these compounds have shown that they prevent the emergence or re-

The emergence of selection pressure-mediated resistance when used in combination regimens with currently marketed antibiotics. StimBiotics intends to break the cycle of “use versus resistance selection” within the prototype antibiotic of each class that we have lost, ultimately recovering and restoring all these antibiotics to their former market position.

In every case, the StimBiotics synergistic combination is a patentable New Antibiotic, resetting the old antibiotic to allow both wide use and preventing further resistance. Antibiotic Stewardship programs will respond by using the version of each old antibiotic that prevents selection pressure resistance and restores its former activity spectrum with the goal to resume front-line use.

NavIntus, Inc.

Navintus Inc. is an early-stage biotechnology company formed in 2021 created by BusStim, LLC, a virtual biotech accelerator and PepVax and its SMARTmidTM vectors for drug delivery. Its mission is to advance groundbreaking DNA-based drug delivery research in the management of chronic pain. Incorporating a “Trojan Horse” platform, this novel DNA plasmid delivery will target the NAv1.7 pathway to offer a non-opioid alternative to chronic moderate-to-severe pain using the patient’s cells for manufacturing the required proteins. Navintus will use the TheraSyn Cholestosome Technology to create an oral product for neuropathic pain